Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.

Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM.

PLoS One. 2018 Feb 1;13(2):e0191890. doi: 10.1371/journal.pone.0191890. eCollection 2018.

2.

IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.

Aleksic T, Verrill C, Bryant RJ, Han C, Worrall AR, Brureau L, Larré S, Higgins GS, Fazal F, Sabbagh A, Haider S, Buffa FM, Cole D, Macaulay VM.

Br J Cancer. 2017 Nov 21;117(11):1600-1606. doi: 10.1038/bjc.2017.337. Epub 2017 Oct 3.

PMID:
28972962
3.

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T.

Target Oncol. 2017 Oct;12(5):571-597. doi: 10.1007/s11523-017-0514-5.

4.

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.

Pirovano G, Ashton TM, Herbert KJ, Bryant RJ, Verrill CL, Cerundolo L, Buffa FM, Prevo R, Harrap I, Ryan AJ, Macaulay V, McKenna WG, Higgins GS.

Br J Cancer. 2017 Aug 8;117(4):503-512. doi: 10.1038/bjc.2017.197. Epub 2017 Jul 4.

5.

Synthesis and bioactivity of fused- and spiro-β-lactone-lactam systems.

Josa-Culleré L, Towers C, Willenbrock F, Macaulay VM, Christensen KE, Moloney MG.

Org Biomol Chem. 2017 Jun 27;15(25):5373-5379. doi: 10.1039/c7ob01148b.

PMID:
28617490
6.

Mitogenome Diversity in Sardinians: A Genetic Window onto an Island's Past.

Olivieri A, Sidore C, Achilli A, Angius A, Posth C, Furtwängler A, Brandini S, Capodiferro MR, Gandini F, Zoledziewska M, Pitzalis M, Maschio A, Busonero F, Lai L, Skeates R, Gradoli MG, Beckett J, Marongiu M, Mazzarello V, Marongiu P, Rubino S, Rito T, Macaulay V, Semino O, Pala M, Abecasis GR, Schlessinger D, Conde-Sousa E, Soares P, Richards MB, Cucca F, Torroni A.

Mol Biol Evol. 2017 May 1;34(5):1230-1239. doi: 10.1093/molbev/msx082.

7.

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.

Aleksic T, Browning L, Woodward M, Phillips R, Page S, Henderson S, Athanasou N, Ansorge O, Whitwell D, Pratap S, Hassan AB, Middleton MR, Macaulay VM.

Front Oncol. 2016 May 2;6:98. doi: 10.3389/fonc.2016.00098. eCollection 2016.

8.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

9.

Resolving the ancestry of Austronesian-speaking populations.

Soares PA, Trejaut JA, Rito T, Cavadas B, Hill C, Eng KK, Mormina M, Brandão A, Fraser RM, Wang TY, Loo JH, Snell C, Ko TM, Amorim A, Pala M, Macaulay V, Bulbeck D, Wilson JF, Gusmão L, Pereira L, Oppenheimer S, Lin M, Richards MB.

Hum Genet. 2016 Mar;135(3):309-26. doi: 10.1007/s00439-015-1620-z. Epub 2016 Jan 18.

10.

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.

Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N, Dianov GL, Verrill C, Macaulay VM, Ying S, La Thangue NB, D'Angiolella V, Ryan AJ, Humphrey TC.

Cancer Cell. 2015 Nov 9;28(5):557-568. doi: 10.1016/j.ccell.2015.09.015.

11.

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Ramcharan R, Aleksic T, Kamdoum WP, Gao S, Pfister SX, Tanner J, Bridges E, Asher R, Watson AJ, Margison GP, Woodcock M, Repapi E, Li JL, Middleton MR, Macaulay VM.

Oncotarget. 2015 Nov 24;6(37):39877-90. doi: 10.18632/oncotarget.5631.

12.

IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer.

Dale OT, Aleksic T, Shah KA, Han C, Mehanna H, Rapozo DC, Sheard JD, Goodyear P, Upile NS, Robinson M, Jones TM, Winter S, Macaulay VM.

Carcinogenesis. 2015 Jun;36(6):648-55. doi: 10.1093/carcin/bgv053. Epub 2015 Apr 20.

PMID:
25896444
13.

Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.

Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM.

Int J Cancer. 2015 Jun 15;136(12):2961-6. doi: 10.1002/ijc.29327. Epub 2014 Nov 25.

14.

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM.

Cancer Res. 2014 Oct 15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 2014 Aug 28.

15.

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King H, Aleksic T, Haluska P, Macaulay VM.

Cancer Treat Rev. 2014 Oct;40(9):1096-105. doi: 10.1016/j.ctrv.2014.07.004. Epub 2014 Aug 4. Review.

16.

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.

Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM.

Oncogene. 2014 Nov 6;33(45):5262-73. doi: 10.1038/onc.2013.460. Epub 2013 Nov 4.

17.

A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages.

Costa MD, Pereira JB, Pala M, Fernandes V, Olivieri A, Achilli A, Perego UA, Rychkov S, Naumova O, Hatina J, Woodward SR, Eng KK, Macaulay V, Carr M, Soares P, Pereira L, Richards MB.

Nat Commun. 2013;4:2543. doi: 10.1038/ncomms3543.

18.

Evaluating purifying selection in the mitochondrial DNA of various mammalian species.

Soares P, Abrantes D, Rito T, Thomson N, Radivojac P, Li B, Macaulay V, Samuels DC, Pereira L.

PLoS One. 2013;8(3):e58993. doi: 10.1371/journal.pone.0058993. Epub 2013 Mar 22.

19.

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM, Ritchie AW, Eisen T, Macaulay VM, Protheroe A.

BMC Cancer. 2012 Dec 11;12:590. doi: 10.1186/1471-2407-12-590.

20.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC.

Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.

Supplemental Content

Loading ...
Support Center